Bristol-Myers Squibb stock (US1078421011): $15.2B China drug deal

Bristol-Myers Squibb announced a major collaboration with China's Jiangsu Hengrui Pharma worth up to $15.2 billion, targeting oncology and immunology assets. The stock opened at $56.40 on NYSE amid Q1 earnings beat.

Bristol-Myers Squibb has entered a landmark global collaboration with Jiangsu Hengrui Pharmaceuticals, potentially worth up to $15.2 billion in milestone payments across 13 early-stage drug programs in oncology, hematology, and immunology, according to MarketBeat as of 05/14/2026. This deal aims to bolster the company's pipeline as it faces patent cliffs on blockbuster drugs. Separately, the firm reported Q1 2026 results with EPS of $1.58 beating estimates on $11.49 billion revenue, while maintaining its $0.63 quarterly dividend.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bristol-Myers Squibb
• Sector/industry: Biotechnology / Pharmaceuticals
• Headquarters/country: United States
• Core markets: US, Europe, Asia
• Key revenue drivers: Oncology, immunology, cardiovascular drugs
• Home exchange/listing venue: NYSE (BMY)
• Trading currency: USD

Bristol-Myers Squibb: core business model

Bristol-Myers Squibb focuses on discovering, developing, and delivering innovative medicines for serious diseases, with a portfolio centered on oncology, hematology, immunology, cardiovascular, and fibrosis treatments. The company operates globally, leveraging R&D investments to advance novel therapies like checkpoint inhibitors and cell therapies. In 2025, it generated significant revenue from drugs such as Opdivo and Eliquis, according to its annual report published in early 2026.

This biopharma giant employs a strategy of internal innovation combined with strategic partnerships to refresh its pipeline, addressing upcoming revenue gaps from patent expirations. The recent Hengrui deal exemplifies this approach, granting access to promising assets from one of China's leading pharma firms.

Main revenue and product drivers for Bristol-Myers Squibb

Key products include Opdivo (nivolumab) for cancer immunotherapy, which drove substantial growth in Q1 2026 with oncology revenue forming over 40% of total sales, per the earnings release on MarketBeat as of 05/14/2026. Eliquis (apixaban) remains a cardiovascular staple, while newer launches like Camzyos target niche indications.

The Q1 2026 results showed revenue of $11.49 billion, surpassing expectations, with EPS at $1.58. The company reaffirmed its full-year guidance, highlighting growth in growth products offsetting declines in mature portfolio items.

Industry trends and competitive position

The biopharma sector faces pressures from biosimilar competition and pricing reforms, yet oncology remains a high-growth area with demand for next-gen therapies. Bristol-Myers Squibb holds a strong position with its leadership in immuno-oncology, competing with Merck and Roche. The Hengrui partnership expands its reach into Asia's burgeoning biotech scene, potentially accelerating pipeline diversification.

Why Bristol-Myers Squibb matters for US investors

As a NYSE-listed blue-chip with heavy US revenue exposure (over 50% of sales), Bristol-Myers Squibb offers US investors stability in healthcare amid economic cycles. Its dividend yield of approximately 4.5% based on the maintained $0.63 quarterly payout appeals to income-focused portfolios, while pipeline deals signal innovation relevant to the world's largest pharma market.

Conclusion

Bristol-Myers Squibb's $15.2 billion Hengrui collaboration underscores its commitment to pipeline renewal, complemented by solid Q1 results and steady dividend policy. While facing patent challenges, strategic deals position it for long-term competitiveness in biopharma. Investors track upcoming milestones and earnings for further insights into execution.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.